PropThink wrote that the management team at Galena Biopharma (Nasdaq: GALE) was incompetent and that the biotechnology company reported inaccurate clinical trial results sending the stock price tumbling 63 cents to close at $1.40.
Galena Management Criticized
November 12, 2012 at 17:08 PM EST
